A practical reference on fatty acid oxidation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-23 and is reviewed periodically as new material appears.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
John Cox Stevens (1803), founder and first commodore of the New York Yacht Club, won the first America's Cup trophy in 1851 Reginald Sayre (1881), orthopedic surgeon and Olympic sport shooter Charles Sands (1887), athlete who won the gold medal in Golf at the 1900 Summer Olympics Oliver Campbell (1891), tennis player; youngest male winner of the US Open Singles title 1890–1990 Charles Townsend (1893), first Olympic fencer from the Ivy League; silver medalist in the 1904 Summer Olympics Gustavus Town Kirby (1895), president of the United States Olympic Committee 1920–1924, and Amateur Athletic Union 1911–1913 Leo Fishel (1899), first Jewish pitcher in Major League Baseball Harold Weekes (1903), football player for the Columbia Lions, member of the College Football Hall of Fame Harry A. Fisher (1905), basketball coach for Columbia, United States Military Academy, St. John's; member of the Basketball Hall of Fame Robert LeRoy (1905), two-time silver medalist in the 1904 Summer Olympics Eddie Collins (1907), baseball player for the Chicago White Sox and member of the Baseball Hall of Fame Marcus Hurley (1908), cyclist who won four gold medals in Cycling at the 1904 Summer Olympics Jay Gould II* (1911), real tennis player, Olympic gold medalist in 1908 and world champion 1914–1916; great-grandson of financier Jay Gould Ted Kiendl (1911), National Basketball Player of the Year in 1911; corporate lawyer, argued Erie Railroad Co. v.
Laboratory LOINC: It covers laboratory tests, microbiology tests (including antibiotic susceptibilities) Clinical LOINC: It covers a variety of non-lab concepts (ECG concepts, cardiac echo, obstetric ultrasound). Within clinical LOINC, there are also sup-parts for Clinical documents: concepts for various types of clinical reports (e.g., discharge summary, well-child visit note) Survey instruments: concepts for standardized surveys (e.g., Glasgow Coma Score, PHQ-9 depression scale)
Chemically, levorphanol belongs to the morphinan class and is (−)-3-hydroxy-N-methyl-morphinan. It is the "left-handed" (levorotatory) stereoisomer of racemorphan, the racemic mixture of the two stereoisomers with differing pharmacology. The "right-handed" (dextrorotatory) enantiomer of racemorphan is dextrorphan (DXO), an antitussive, potent dissociative hallucinogen (NMDA receptor antagonist), and weakly active opioid. DXO is an active metabolite of the pharmaceutical drug dextromethorphan (DXM), which, analogously to DXO, is an enantiomer of the racemic mixture racemethorphan along with levomethorphan, the latter of which has similar properties to those of levorphanol.
Sources: en.wikipedia.org
== Endocrine system == Adrenocortical adenoma Adrenocortical carcinoma Carcinoid Gastrinoma Glucagonoma Insulinoma Islet cell carcinoma (endocrine pancreas) Merkel cell carcinoma Multiple endocrine neoplasia syndrome Pancreatic cancer Parathyroid cancer Pheochromocytoma Somatostatinoma Thyroid cancer VIPoma
AMP deaminase deficiency (formally known as myoadenylate deaminase deficiency or MADD) is a metabolic myopathy which results in excessive AMP buildup brought on by exercise. AMP deaminase is needed to convert AMP into IMP in the purine nucleotide cycle. Without this enzyme, the excessive AMP buildup is initially due to the adenylate kinase (myokinase) reaction which occurs after a muscle contraction. However, AMP is also used to allosterically regulate the enzyme myophosphorylase (see Glycogen phosphorylase § Regulation), so the initial buildup of AMP triggers the enzyme myophosphorylase to release muscle glycogen into glucose-1-P (glycogen→glucose-1-P), which eventually depletes the muscle glycogen, which in turn triggers protein metabolism, which then produces even more AMP. In AMP deaminase deficiency, excess adenosine is converted into uric acid in the following reaction:
== Background == The conflict occurred against the backdrop of long-running tensions between Afghanistan and Pakistan rooted in disputes dating back to the independence of Pakistan in 1947. Afghanistan has historically challenged the legitimacy of the Durand Line, which forms the international border between the two nations, contributing to decades of strained relations and periodic clashes. Relations deteriorated further following the Taliban's return to power in 2021 in the aftermath of the US withdrawal from Afghanistan. Pakistan has repeatedly accused Afghanistan of providing safe haven to militant groups, particularly the Tehreek-e-Taliban Pakistan (TTP), which has carried out attacks in Pakistan in order to establish an Islamic emirate, similar to the model of government in Afghanistan. Taliban authorities have generally denied these allegations. Tensions escalated in 2025 after a surge in cross-border violence and militant attacks. In October 2025, some of the deadliest clashes in years led to a Qatar-mediated ceasefire, but its implementation proved to be fragile, and follow-up talks in Doha and Istanbul failed to produce a lasting agreement. Low-level skirmishes continued along the border in the following months. In early 2026, Pakistan experienced a series of major attacks, primarily in its frontier provinces of Balochistan and Khyber Pakhtunkhwa, alongside a major suicide bombing in the capital of Islamabad.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.